Boston Life Sciences Reports New Option Grants Under NASDAQ Market Rule 4350.

BOSTON -- Boston Life Sciences, Inc. (NASDAQ: BLSI) today announced, in accordance with NASDAQ Marketplace Rule 4350, as amended, it granted inducement stock options in connection with the commencement of employment of three new employees. The new employees are Mary Wallace, Director of Strategic Marketing and Commercialization; Sharon Correia, Director of Corporate Communications and Investor Relations; and Fraser McNeilly, Director of Information Technology. A total of 39,500 nonqualified options were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv). The options were issued with an exercise price equal to the fair market value on June 2, 2005, or $2.24, have a ten year duration and will vest ratably over the next 36 months.

"We are pleased that these individuals are joining Boston Life Sciences", stated Dr. Mark Pykett, the Company's President. "Each person brings an important set of skills to the organization. Mary Wallace brings years of product management, sales, marketing and strategy experience in nuclear medicine imaging and will focus on evaluating the range of marketing possibilities and accelerating partnering opportunities for our products. Sharon Correia has extensive expertise in building franchises in the neurology and Parkinson's communities and will drive awareness of our programs within the investor community and among patient advocacy groups. Fraser McNeilly will strengthen our information technology infrastructure as we ramp up the quality program and regulatory compliance for our products and implement section 404 of the Sarbanes Oxley Act of 2002."

Boston Life Sciences, Inc. (BLSI) is a biotechnology company primarily focused in the research and clinical development of biopharmaceutical products for the diagnosis and treatment of central nervous system, or CNS, diseases.

Statements in this press release regarding management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in the Company's Annual Report on 10-K for the year ended December 31, 2004, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, the Company's actual results may differ materially from the results discussed in or implied by the forward-looking statements contained herein. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will" and "would" or similar words. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Our logo, trademarks, and service marks are the property of Boston Life Sciences, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Boston Life Sciences, Inc.